A whole-blood transcriptional signature associated with obstructive post-tuberculosis lung disease
Authors:
- Renee E. NewbyRNRenee E. Newby
- Lucy KijaroLKLucy Kijaro
- Kimberly A. Dill-McFarlandKDKimberly A. Dill-McFarland
- Lilian N. NjagiLNLilian N. Njagi
- Wilfred B. MurithiWMWilfred B. Murithi
- Jodi ByersJBJodi Byers
- Glenna J. PetersonGPGlenna J. Peterson
- Kevin P. FennellyKFKevin P. Fennelly
- Videlis NdubaVNVidelis Nduba
- David J. HorneDHDavid J. Horne
Preprint
Abstract
Background: Post-tuberculosis (TB) lung disease (PTLD) affects approximately 50% of persons with pulmonary TB. We recently discovered whole blood transcriptional signatures associated with PTLD. We examined whether a minimum gene signature predicts PTLD as a clinically useful biomarker. Methods: We prospectively enrolled 301 treatment naïve adults with newly diagnosed pulmonary TB (PTB) (cohort A). We collected whole blood at 0 and 6-month visits, isolated RNA, and measured a modified MTB Host Response (HR) signature (mHR) based on expression of DUSP3, GBP5, and TMBIM6. We recorded spirometry at 6 (n=216) and 12 months (n=210) after treatment initiation and examined the association of the mHR score with PTLD and Mtb aerosolization. We recruited household contacts of cohort A to compare mHR score with non-PTB participants (cohort B). Findings: mHR was associated with TB (p=4.15e-66) when compared to HHCs, treatment response (p=1.07e-53), and characteristics including CD4 count (p=0.003), bacillary load (p=3.02e-05), lung cavities (p=1.59e-04), and lung quadrants involved (p=3.87e-06). The mHR score was not associated with Mtb aerosolization. In total, 105 (50%) participants had PTLD at 12 months including 61 with restriction, 26 with obstruction, and 18 with mixed obstruction and restriction. Baseline mHR was associated with obstructive PTLD at both 6 (p=0.003) and 12 months (p=0.012) in bivariate and multivariate analyses. The mHR score was not associated with restrictive lung disease. Interpretation: Baseline mHR was associated with obstructive PTLD at 6 and 12 months and may have applications in targeting treatment and prognostication.Keywords
This publication has 35 references indexed in Scilit:
- RNA-binding protein AZGP1 inhibits epithelial cell proliferation by regulating the genes of alternative splicing in COPDGene, 2024
- Diagnostic accuracy of a three-gene Mycobacterium tuberculosis host response cartridge using fingerstick blood for childhood tuberculosis: a multicentre prospective study in low-income and middle-income countriesThe Lancet Infectious Diseases, 2023
- Guanylate-binding proteins: mechanisms of pattern recognition and antimicrobial functionsTrends in Biochemical Sciences, 2023
- Blood-based host biomarker diagnostics in active case finding for pulmonary tuberculosis: A diagnostic case-control studyeClinicalMedicine, 2021
- Assessment of Validity of a Blood-Based 3-Gene Signature Score for Progression and Diagnosis of Tuberculosis, Disease Severity, and Treatment ResponseJAMA Network Open, 2018
- A blood RNA signature for tuberculosis disease risk: a prospective cohort studyThe Lancet, 2016
- Guanylate Binding Protein (GBP) 5 Is an Interferon-Inducible Inhibitor of HIV-1 InfectivityCell Host & Microbe, 2016
- Genome-wide expression for diagnosis of pulmonary tuberculosis: a multicohort analysisThe Lancet Respiratory Medicine, 2016
- Prevalence of chronic obstructive pulmonary disease and associated risk factors in Uganda (FRESH AIR Uganda): a prospective cross-sectional observational studyThe Lancet Global Health, 2015
- Risk loci for chronic obstructive pulmonary disease: a genome-wide association study and meta-analysisThe Lancet Respiratory Medicine, 2014